CASI Pharmaceuticals Receives Drug Registration Certificate for Thiotepa in China
I'm PortAI, I can summarize articles.
CASI Pharmaceuticals Inc. has received a Drug Registration Certificate for Thiotepa for Injection in China, valid until February 1, 2031. The company holds exclusive distribution rights from ESTEVE Pharmaceuticals GmbH. CASI plans to transfer all rights related to Thiotepa in China, excluding Hong Kong, Macau, and Taiwan, to Kaixin Pharmaceuticals Inc.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments